Gallos et al., in their 2018 Cochrane review on uterotonics for PPH, identified that Ergometrine plus oxytocin combination, carbetocin, and misoprostol plus oxytocin combination may have some additional desirable effects compared with the current standard oxytocin. The gene discussed is OXT; the disease is pulmonary arterial hypertension.